Table 4.
Pharmacokinetic parameters of VST in various formulations in rats.
| Parameters | Raw VST | Diovan® | S-SuSMED-T1 | S-SuSMED-T2 |
|---|---|---|---|---|
| AUC0–24h (ng·h/mL) | 7799.7 ± 3643.8 | 8381.2 ± 6086.1 | 15432.6 ± 5538.3 | 14867.6 ± 6092.9 |
| Cmax (ng/mL) | 732.7 ± 372.9 | 880.0 ± 841.0 | 2092.6 ± 528.5 | 2156.0 ± 803.0 |
| Tmax (h) | 3.0 ± 1.4 | 2.1 ± 1.2 | 0.9 ± 0.3 | 1.1 ± 0.5 |
| Relative BA (%) | ||||
| versus raw VST | – | 107.5 | 197.9 | 190.6 |
| versus Diovan® | 93.1 | – | 184.1 | 177.4 |
Values are presented as the mean ± SD (n = 8–12). AUC: area under the curve; BA: bioavailability.